# Trial of TG4023 Combined With Flucytosine in Liver Tumors

> **NCT00978107** · PHASE1 · COMPLETED · sponsor: **Transgene** · enrollment: 16 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** MVA-FCU1, flucytosine

## Key facts

- **NCT ID:** NCT00978107
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00978107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00978107, "Trial of TG4023 Combined With Flucytosine in Liver Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00978107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*